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Human T-cell leukemia virus type I (HTLV-I) protease has been purified to homogeneity from a strain ofrecombinant Exherickic~ co/i. The protease 
was expressed as a larger precursor, which was autoprocessed to form a mature protease. Protein chemical analyses revealed the coding sequence 
of mature protease, which agreed with the putative sequence predicted from the sequence of bovine leukemia virus protease. The purified proteasc 
processed the natural substrate gcr.5 precursor (~53) to form gag pl9 and gig ~24. The protease activity was inhibited by pepstatin A. These results 
provide direct evidence that this protease belongs to theaspartic protcase family and has an activity consistent with the protease in HTLV-I virion. 
HTLV-1 protcase; Aspartic protease: gag precursor 
1. INTRODUCTION 
Human T-cell leukemia virus type I (HTLV-I) is a 
retrovirus causing adult T-cell leukemia (ATL) and 
HTLV-I-associated myelopathy (HAM) [I-S]. The 
HTLV-I genome has been cloned from the peripheral 
blood leukocytes of an ATL patient, and subsequent 
characterization of the viral genome has revealed that 
it is composed of gag, pal, env, and pX genes [4]. HTLV- 
I proteins, like other retroviral proteins. are initially 
translated as the large precursor polyproteins, which 
are proteolytically processed to generate structural pro- 
teins (pl9. p24, pl5). enzymes (protease. reverse tran- 
scriptase, and integrase), and envelope proteins [5-l 11. 
Processing of the gug and pal polyproteins is catalyzed 
by a viral-encoded specific protease [5-121. Nam and 
Hatanaka [13] first demonstrated the nucleotide se- 
quence of the protease from replication-competent pro- 
virus HTLV IC [ 141. The open reading frame (ORF) for 
the protease (prt) is located between gag and pal and is 
different from those for gag and pol. Therefore. the 
oicurrcnce of two frameshift events is believed to be 
necessary for the replication of the virus [15]. 
both of which occur in a sequence-DTG-. The retroviral 
proteases contain only one such-DTG-sequence and 
their molecular weights are slightly less than half the 
size of typical aspartic proteases [17]. Recently, recom- 
binant human immunodeficiency virus 1 (HIV-I) prote- 
ase was obtained using a genetic engineering technique 
[IS-211, which made it possible to investigate the bio- 
chemical properties of the protease and its inhibitors. 
Furthermore, the X-ray crystallographic analyses of 
HIV-l protease [22] and avian retroviral protease [23] 
have revealed that these proteases exist as a dimer of 
identical subunits. 
In this paper, we describe the purification of enzyma- 
tically active HTLV-1 protease expressed in recombi- 
nant Eschet-ia co/i cells and the characterization of the 
purified enzyme. 
2. MATERIALS AND METHODS 
The putative amino acid sequence deduced from the 
ORF for the HTLV-I protease has suggested that it 
belongs to the family of aspartic proteases, like other 
retroviral proteases [13.15,16]. The active sites of cellu- 
lar aspartic proteases contain two aspartic residues. 
The expression of HTLV-I proteasc in E. cali will bc published 
elsewhcrc. In brief, 750 bp rMboll-EroRI fragment of p7.5gagfslY [IS] 
containing the 3’porlion ofg(Jg and the entircprl was ligated with an 
AI-G-linker and the resulting 760 bp fragment was cxpresscd in E. co/i 
under the control of B T7 promoter. A transformant. E. co/i 
MM294[DE3]lpHTl7707. was cultured at 37°C in LB medium and 
HTLV-I protcasc was produced after induction with 0. I mM isopro- 
pyl B-D-tlriogalactosidc. 
2.2. Pur#catiotr of NTLV-I prrrtccr,sc 
Cf~rrrs/~clrrclo~c.c crclclrcs.s: M. Kobayashi, Biotechnology Rcscarch La- 
boratorics. Rcscarch and Dcvclopmcnt Division, Takcda Chemical 
lndustrics Ltd., Jusohonmachi 2.chomc. Yodogawa-ku, Osaka 532, 
Japan. F;Ix: (81) (6) 300 6306. 
All the solutions used contained 0.1% nonidct 1’40 (NPJO), IO% 
glycerol. 5 mM EDTA, I mM phcnylmcthylsulfonyl fluoridc(PMSF). 
0.1 mM (~amidino~pl~enyllmctl~anssulfonyl iluoridc (APMSF). 
0.02% 2.mcrcaptocthanol (?-hlE). r. w/i MM294[DE3]/pHTI 17707 
cells wcrc suspcndcd it1 SO mM Tris-HCI (pH 7.6), 1% NP40. 100 
//g/ml egg white lysozymc (Scikiigaku Kogyo Co.). The CCIIS wcrc 
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disrupted by sonication. The crude extract was obtained by centrifuga- 
tion, diluted with 4 vols. of 10 mM sodium phosphate buffer (pH 6.0). 
and loaded onto an S-Sepharose fast-flow (Pharmacia) column (2.5 x 
25 cm) equilibrated with the same buffer. HTLV-I protease was eluted 
with a gradient of NaCl concentrations. The crude protease from the 
S-Sepharose column was conccn:rated with a YM 5 membrane, and 
loaded onto a Sephacryl S-IOOHR (Pharmacia) column (5 x 82 cm) 
equilibrated with 50 mM sodium phosphate buffer (pH 6.0) and 0.1 
M Na,SO,. The fractions containing the active protease were pooled, 
diluted with 20 mM CH,COONH, buffer (pH 5.5), and loaded onto 
a mono S colunn (Pharmacia: 0.5 x 5 cm). HTLV-I protcasc was eluted 
with a gradient of NaCl concentrations. The fractions containing the 
active protease were pooled and re-chromatographed on the same 
column. The frac!ions containing the purified protease were collected 
and stored at -80GC before use. 
2.3. Preparation OJ reconrhitrant HTL V-I gag ~53 
The expression and purification of recombinant HTLV-I gag p53 
in Succharon~;~eu c rerisiue (NA74-3Ap.lpliTl5 I I) will be described 
elsewhere. In brief, recombinant yeast cells expressing HTLV-I gag 
~53 were disrupted by BEAD-BEATER (Biospec Products) and cen- 
trifuged. The microsomal fraction was obtained by ultracentrifugation 
and gag ~53 was purified by Butyl-Toyopearl 650M (Tosoh) and 
Protein PAK G-CM (Waters) column chromatography. 
2.4. Dekwlinarion of prorcase crclivif_v 
T!le activity of the HTLV-I protease was determined by measuring 
the rate of hydrolysis of a synthetic peptide. gag-l (YVEP- 
TAPQVLPVMHP). Gag-l (I 2 pg) was dissolved in 30 fll of 100 mM 
sodium citrate buffer (pH 5.0). The reaction was initiated by the 
addition of the protease. and the reaction mixture was incubated at 
37OC for 1 h. The reaction was terminated by adding trichloroacetic 
acid and the quantity of a product peptide, YVEPTAPQVL. was 
determined with reverse-phase HPLC using a Y MC-PACK FL-ODS 
column (Yamamura Kagaku; 4.6 x 30 mm). Pepstatin A used for 
inhibition studies was purchased from Sigma and dissolved in dimeth- 
yl sulfoxide at IO me/ml before use. 
The N-terminal amino acid sequence was dctermincd with a @S- 
phase protein sequencer model 470A and a model IZOA analyzer 
(Applied Biosystems Inc.). Amino acids at the C-terminal region were 
determined by hydrazinolysis [24] and carboxy peptidase Y digestion. 
Amino acid composition was determined with a PICO-TAG amino 
acid analysis system (Waters). 
3. RESULTS 
Western blotting analysis of a cell free extract of E. 
coli MM294[DE3]/pHTI7707 gave a band with an M, 
of 14 000 which was reactive to anti-HTLV-I protease 
antibodies (Fig. 1A). Purification of the recombinant 
HTLV-I protease was monitored by the peptidolytic 
assay using YVEPTAPQVLPVMHP (gag-l) which has 
the gllg pl9/p24 cleavage site between Leu’“’ and Pro”’ 
in gl/g ~53. Treatment of gag-l with the active protease 
resulted in a time-dependent decrease of the substrate 
on high performance liquid chromatography analysis 
and a concomitant increase of 2 peaks, which comigrat- 
cd with the chemically synthesized anticipated products, 
YVEPTAPQVL (gag-3) and PVMHP (gag-2), confirm- 
ing the position of the cleavage site within the peptide 
(data not shown). A summary of the purification is 
shown in Table I. The SDS-polyacrylamide gel clectro- 
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Fig. I. (A) Immunoblotting of a cell free extract of E. co/i expressing 
HTLV-I orotease: (B) SDS-PAGE of ourificd HTLV-I oro:ease. SDS- 
PAGE was carriedbut according to tie method of LaeAmli [2S] using 
18% (A) and 15% (B) acrylamide gels. (A) HTLV-I protease was 
devclopcd with the affinity-purified anti-protease peptide (DPARRP- 
VIKAQVDTQTS, I-7) rabbit IgG and HRP-conjugated goat anti- 
rabbit IgG. The marker proteins used were prcstained standards from 
BRL. (B) Protein bands were stained with silver staining reagent. The 
marker proteins used were low mol. wt. standards from Bio-Rad. 
phoresis (SDS-PAGE) pattern of the purified protease 
under reducing conditions is shown in Fig. IB. Major 
and minor bands with M,s of 14 400 and 28 600, respec- 
tively, were detected. Each band was reactive to anti- 
protease antibodies (data not shown), so these 2 bands 
were judged to be monomer and dimer forms of the 
mature protease. The purity was estimated to be greater 
Table I 
Summary of the ourification of HTLV-I protcase 
seep Volume 
(ml) 
Extract 
S-Scpharosc 
Sephacryl S- 
IOOHR 
Mono S 1st 
Mono S 2nd 
2500 
700 
305 
320 
375 
Total Total Spcciiic Yield 
protein’ activity’ activity 
(m6) (mu) (mU/mg) (%) 
13500 7800 0.58 100 
IGI 4259 26.5 5s 
33 2517 76.0 32 
I6 1556 96.6 20 
7 826 I I I.0 II 
‘Protein content was determined by micro BCA protein assay (Pierce) 
using bovine serum albumin as standard 
‘One unit of the cnzymc activity was dclincd as the amount ofcnzymc 
that foonncd I flmol of g;lg-3/min in the standard assay 
107 
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40 
HTLV-I -LNQD PASI&IPL DPARR PVIKA m- -QTSH -e-e 
BLV PLSEA :LDEC?%IPL ARSRP SVAVV ;;GPW LQPSQ NCIAL- M LVDTG AENT 
MB, 
DO 100 120 
HTLV-I VLPIA LFSSN TPLKN TSVLG AGGQT ODHFK LTSLP VLIRL PFRTT PIVLT 
BLV VLPQN WLVRD YPRIP AA;LG AGGVS RNRYN WL'JGP LTLAL KPEGP FITIP 
120 
140 
IITLV-I SCLVD TKNNU A IIGRDAL QQ CQGVL YLPEA KGPPV I-%J APAV- LGLEH 
cl 
-- 
BLV KILVD ;:;K!4 Q ILGRDVL SR LQASI ;;;EE VRPPH "%LD APPSH IGLEH 
Fig. 2. Putative amino acid sequences of prf of HTLV-I [ 131 and BLV 
[6,1 I]. Arrows indicate putative autoprocessing sites; boxes indicate 
conserved regions in aspartic proteases: *,putative active site of aspar- 
10 60 80 100 120 
Fraction nmber 
tic proteases. 
than 95% by densitometric analysis. The amount of the 
purified HTLV-I protease obtained was 7 mg starting 
from 20 liter of culture. This preparation was used as 
HTLV-I protease throughout the present work. 
Fig. 3. Analytical gel filtration of HTLV-I protease. Purified HTLV-I 
protease (1 mgKl.5 ml) was loaded on a Hi-Load 16/60 Sephacryl 
S-ZOOHR column (Pharmacia; I .6 x 60 cm) equilibrated with 50 mM 
sodium phosphate buffer (pH 6.0), 0.1 M NarSO,, 0.1% NP40, 10% 
glycerol, 5 mM EDTA. I mM PMSF. 0.1 mM APMSF, 0.02% 2-ME 
at a flow rate of 30 ml/h. (0). protease activity; (0). protein concentra- 
tion; arrows indicate peaks of marker proteins: A, bovine serum albu- 
min(66 200): B, ovalbumin (45 000): C. chymotrypsinogen A(25 700): 
D. ribonuclease A (I 3 700). 
3.2. Protein chemical properties 
To determine the region which codes for the active 
protease. the N- and C-terminal amino acid sequences 
were analyzed. The N-terminal amino acid sequence of 
the purified protease was found to be PVIPLDPARRP- 
VIKAQVDT-. The C-terminal amino acid was found to 
be Leu by the hydrazinolysis method. Since carboxy 
peptidase Y released Leu, Ile and Val from the purified 
protease the C-terminal amino acid sequence was deter- 
mined to be -VIL. The N- and C-terminal sequences 
were identical to those in the putative HTLV-I protease 
sequences predicted from that of bovine leukemia virus 
(BLV) protease (Fig. 2). Amino acid composition of the 
purified protease also agreed with that calculated from 
the deduced amino acid sequence consisting of 125 resi- 
dues. 
peptide hydrolytic activity obeyed simple Michaelis- 
Menten kinetics: a K,,, value of 0.50 mM and a k,;,, value 
of 0.085 see-’ were obtained at pH 5.0 by Woolf plot. 
The K,,, value for gag-l changed remarkably depending 
on the concentration of (NH&Sod. In the presence of 
0.5 M (NH&Sod, the K, value decreased by 20-fold. 
whereas the k,:,, value was not affected. 
Pepstatin A. a typical inhibitor of aspartic proteases. 
inhibited the proteolysis of gag-l by HTLV-I protease. 
12 34 
Analytical gel filtration of the purified HTLV-I prote- 
ase demonstrated that the activity was eluted with an M, 
of 27 000 at a position just prior to the protein standard 
chymotrypsinogen A (M, 25 700, Fig. 3). The M, of 
native protease obtained was nearly twice that calculat- 
ed from the amino acid sequence consisting of 125 
residues (M, 13 459. Fig. 2) and that determined by 
SDS-PAGE (M, I4 400. Fig. IB). 
75.0 - 
50.0 - 
39.0 - 
27.0 - 
3.3. Enqvnatic properties 17.0 - 
On incubation with gag ~53, the protease generated 
2 new bands with M,s of 19 000 and 24 000 which were 
detected with anti-HTLV-I gug monoclonal antibodies. 
GIN-7 (anti-p19) and NOR-1 (anti-p24), respectively 
(Fig. 4). These results suggested that the HTLV-I prote- 
ase expressed in the bacterial cells had the ability to 
cJeave the natural substrate, gag precursor, as well its 
the synthetic peptide. 
The optimum pH for hydrolytic activity of thp syn- 
thetic peptide was 5. A similar pH-depcndcncc was ob- 
scrvcd for the cleavage of natural substrate gug ~53. The 
Fig. 4. Processing of gc~g precursor ~53. HTLV-I gcr~ precursor p53 
was incubated with HTLV-I proteasc for 3 h at 37°C. The reaction 
was tcrrninatcd by adding SDS-PAGE sample buffer and heating at 
IODOC for 5 min. SDS-PAGE and immunoblotting were carried OUI 
by using anti-p19 mouse monoclonal IgG. GIN-7. and tbc anti-p24 
mouse monoelonal IgG. NOR-I: (LMCS l-3) trcatcd with buffer 0111~: 
(lanes 2-4) trcatcd with HTLV-I protcasc. Lanes 1 and 2 wcrc dcvclop- 
cd with GIN-7 and lanes 3 and 4 with NOR-I, ‘flc nwkcr proteins 
used wcrc prestaincd standrrds from Bio-Rad. 
- 
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The Ki value for pepstatin A was determined to be 17 
PM, which was far greater than those for pepsin (0.045 
nM), cathepsin D (0.1 nM) and HIV protease (0.5 PM). 
The Ki value was reduced to 2.2 PM in the presence of 
0.5 M (NH&SC%,. 
4. DISCUSSION 
It was postulated that the HTLV-I genome encoded 
a protease essential for the virus’ replication based on 
analogy with other retroviruses [5,6,9-l 1,213. We have 
already reported the ORF encoding HTLV-I protease 
[13], but the structure of the mature protease and its 
biochemical properties have remained to be clarified. 
Here, we have reported the production of the active 
HTLV-I protease in E. coii, which made it possible to 
investigate its biochemical properties. As there was no 
direct information for the region encoding the mature 
protease, the protease was designed to be expressed as 
a larger precursor in E. coli cells. Protein chemical ana- 
lyses of the purified protease have revealed that both N- 
and C-terminal peptides are released on cleavage of the 
peptide bonds between Leu3’ and Pro33 and between 
Leu”’ and Pro”‘, respectively, to form the mature pro- 
tease composed of 125 amino acid residues (Fig. 2). 
Therefore, this protease is thought to recognize its own 
N- and C-terminal sequences and to autoprocess itself 
exactly. This is the first report that directly shows the 
structure of mature HTLV-I protease. The analytic?1 
gel filtration revealed that the Zl4, of the native protcase 
was almost twice that calculated from the amino acid 
sequence, suggesting that the proteasc existed as a dinner 
like other retroviral proteases such as HIV-l and avian 
retroviral proteases [2 1,261. 
We reported that replacing Asp” in the putative X- 
tive site with Gly resulted in the abolishment of proces- 
sing of the gng precursor in cells infected by recom- 
bimnt vaccinia virus [I5]. We have also found the 
IOSS of autoprocessing activity in E. co/i cells by the 
same replacement (unpublished). These results clearly 
suggest that the protease belongs to aspartic protease. 
Biochemical characterization of the purified HTLV-I 
protease demonstrated that the activity was inhibited by 
pepstatin A, a typical inhibitor of aspartic proteases, 
but the Ki value was far greater than those for other 
aspartic proteases, such as pepsin, cathepsin D, and 
even HIV-I protease. Therefore. HTLV-I protease may 
have an active site somewhat different from those of 
other aspartic proteases. HTLV-I protease seems to be 
less similar to cellular aspartic proteases than HIV-l 
protease as judged by pepstatin A inhibition. There are 
some differences in the predicted amino acid sequences 
of the protease between HTLV-I and HIV-l [27]. The 
differences in the inhibitory effect of pepstatin A might 
reflect the evolutional distance of thcsc two viruses, 
The activity of the HTLV-I protease changed re- 
markably in the prcscnce of (NH&SO+ The K,,, for 
gag-l and Ki for pepstatin A decreased depending or7 
the concentration of (NH&S04, but little change of k,, 
was observed, suggesting that (NH&SO, affects the in- 
teraction between the enzyme and the substrate rather 
than the peptide hydrolytic activity. Similar results were 
reported for the effects of salts on the K,,, values of 
HIV-1 protease [2&l. This property may be common to 
retrovira1 proteases. 
Pathogenic human retroviruses, HTLV-1 and HIV-l, 
are classified as belonging to different groups of retrovi- 
Tuses based cn the differences in their genomic struc- 
tures and pathogenicities. Recently, the HIV-l protease 
was obtained using a genetic engineering technique [ 1% 
211. Here, we have obtained HTLV-I prvtease using the 
same technique and it has become possible to compare 
the biochemical properties of these human retroviral 
proteases with each other and with retroviral proteases 
of different origin. Such information will facilitate the 
investigation of virivn maturation of pathogenic retro- 
viruses and may lead to the discovery of effective agents 
for the treatment of diseases caused by retroviruses. 
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